You are here: Industry Insights > AstraZeneca

News List

AstraZeneca strikes mRNA-based partnership in respiratory disease pharmatimes
August 23, 2017
AstraZeneca and MedImmune, the company’s biologics research arm, have forged a five year research partnership with mRNA-based pulmonary disease specialist Ethris to leverage the latter’s proprietary SNIM RNA technology in the...
Ironwood's gout franchise gets a lift with Duzallo combo approval fiercepharma
August 22, 2017
Ironwood is expecting the Duzallo approval to cue $300 million in peak annual gout sales.
AstraZeneca inks respiratory disease mRNA pact with Ethris fiercebiotech
August 22, 2017
AstraZeneca and Ethris are researching asthma, chronic obstructive pulmonary disease and idiopathic pulmonary fibrosis.
AstraZeneca, MedImmune and Ethris to develop mRNA treatments for respiratory diseases pharmaceutical-technology
August 22, 2017
AstraZeneca, along with its global biologics research and development unit MedImmune, and German biotech Ethris have entered a strategic research collaboration to develop stabilised non-immunogenic modified messenger ribonucleic acid (mRNA) therapies for
FDA expands use of AZ/Merck’s Lynparza in the US pharmatimes
August 21, 2017
AstraZeneca and Merck & Co’s Lynparza will be available to a wider range of patients in the US after regulators expanded the PARP inhibitor’s list of approved uses.
US FDA grants breakthrough therapy designation for AstraZeneca’s MCL treatment pharmaceutical-technology
August 04, 2017
AstraZeneca’s acalabrutinib has received breakthrough therapy designation from the US Food and Drug Administration (FDA) for the treatment of patients...
AstraZeneca, Merck in $8.5B Oncology Pact contractpharma
August 04, 2017
Will co-develop and co-commercialize Lynparza for multiple cancer types
FDA grants priority review to AstraZeneca's filing for BTK inhibitor acalabrutinib in mantle cell ly firstwordpharma
August 03, 2017
AstraZeneca announced Wednesday that the FDA accepted and granted priority review to an application seeking approval of acalabrutinib in patients with relapsed/refractory mantle cell lymphoma (MCL) who have received at least one prior therapy.
AstraZeneca's Priority Review good news provides reprieve pharmafile
August 03, 2017
If there was a company that needed a series of good news stories this week, it was AstraZeneca. The blow of the Mystic trial was enough to have the company seeing stars, and its share value seeing the depths
AstraZeneca scores second accelerated FDA review in 2 days for blood cancer drug pharmafile
August 02, 2017
It’s been a rollercoaster week for AstraZeneca. Following the failure of its crucial Mystic trial for its immunotherapy drug Imfinzi, the company has unloaded a string of positive announcements to neutralise potential damage

Previous page 1 2 3 4 5 6 7 8 9 10 ... 80 81 Next page